Menopause Practice Questions

Q: In menopause, which of the following is not typically observed?

FSH. **Explanation:** In menopause, the primary physiological change is the depletion of ovarian follicles, leading to a significant decrease in estrogen and inhibin levels. This loss of negative feedback on the pituitary gland results in a **marked increase in Follicle-Stimulating Hormone (FSH)** levels. Therefore, a decrease in FSH is **not** observed; rather, an elevation (typically >40 mIU/mL) is the hallmark diagnostic feature. **Analysis of Options:** * **A. FSH (Correct):** As explained, FSH levels rise significantly due to the lack of ovarian feedback. A "decrease" or "lack of observation" of high FSH would be incorrect in a menopausal profile. * **B & D. Cholesterol:** Menopause is associated with an adverse lipid profile. Due to the loss of the cardioprotective effects of estrogen, there is typically an **increase** in Total Cholesterol and LDL, and a decrease in HDL. * **C. Androgen:** While adrenal androgens continue to be produced, overall ovarian androgen production (specifically androstenedione) **decreases** significantly after menopause, although the decline is less absolute than that of estrogen. **High-Yield NEET-PG Pearls:** * **Earliest biochemical marker** of ovarian aging: Decrease in **Inhibin B**. * **Most sensitive/diagnostic marker** for menopause: Elevated **FSH** (>40 mIU/mL). * **Estrogen shift:** The predominant estrogen changes from **Estradiol (E2)** (ovarian source) to **Estrone (E1)** (produced via peripheral conversion in adipose tissue). * **LH levels** also increase, but the FSH rise is more pronounced due to its longer half-life and the specific loss of inhibin.

Q: What is the most common cause of postmenopausal bleeding?

Endometrial atrophy. **Explanation:** **1. Why Endometrial Atrophy is Correct:** Endometrial atrophy is the **most common cause** of postmenopausal bleeding (PMB), accounting for approximately 60–80% of cases. In the postmenopausal state, low estrogen levels lead to a thin, friable endometrial lining. The lack of structural support causes the thin epithelium to shed or the underlying microvasculature to rupture easily, resulting in light spotting or bleeding. **2. Analysis of Incorrect Options:** * **Endometrial Cancer (A):** While this is the most **concerning** cause that must be ruled out, it accounts for only about 10% of PMB cases. * **Endometrial Polyps (B):** These are common benign growths and a frequent cause of PMB (approx. 10–15%), but they are less common than atrophy. * **Endometrial Hyperplasia (D):** This is a precursor to malignancy caused by unopposed estrogen. While significant, it is statistically less frequent than atrophic changes. **3. Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** Fractional Curettage (historically) or Office Endometrial Biopsy (Pipelle). * **First-line Screening:** Transvaginal Ultrasound (TVUS). * **Cut-off Value:** An endometrial thickness (ET) of **≤ 4 mm** in a postmenopausal woman has a high negative predictive value for malignancy. If ET is > 4 mm, a biopsy is mandatory. * **Most common cause of PMB worldwide:** Endometrial Atrophy. * **Most common gynecological malignancy in developed countries:** Endometrial Cancer (In India, it is traditionally Cervical Cancer, though Endometrial Cancer is rising in urban populations).

Q: Hormone replacement therapy in post-menopausal women increases the risk of all the following conditions EXCEPT:

Colorectal cancer. **Explanation:** The question focuses on the findings of the **Women’s Health Initiative (WHI) trial**, which redefined the risks and benefits of Hormone Replacement Therapy (HRT). **Why Colorectal Cancer is the correct answer:** HRT (specifically combined Estrogen and Progesterone) has a **protective effect** against colorectal cancer. Large-scale clinical trials demonstrated a significant reduction (approximately 30-40%) in the incidence of colorectal cancer among women using combined HRT. Therefore, it does not increase the risk; it decreases it. **Analysis of Incorrect Options:** * **Breast Cancer:** Long-term use of combined HRT (Estrogen + Progestogen) is associated with an increased risk of breast cancer. This risk is primarily linked to the progestogen component. * **Stroke:** HRT increases the risk of ischemic stroke. This is part of the overall cardiovascular risk profile associated with oral estrogen therapy in older post-menopausal women. * **Thromboembolism:** Oral estrogen increases the synthesis of clotting factors in the liver (first-pass effect), leading to a 2-to-3-fold increased risk of **Deep Vein Thrombosis (DVT)** and **Pulmonary Embolism**. **NEET-PG High-Yield Pearls:** 1. **Endometrial Cancer:** Unopposed estrogen therapy increases the risk of endometrial cancer; hence, Progesterone is always added if the uterus is intact. 2. **Fracture Risk:** HRT is highly effective in reducing the risk of **osteoporotic fractures** (hip and spine). 3. **Lipid Profile:** HRT typically increases HDL and decreases LDL, but it also increases **Triglycerides**. 4. **Gallstones:** HRT increases the risk of cholelithiasis due to increased cholesterol saturation of bile. 5. **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60.

Q: A 48-year-old female with severe dysfunctional uterine bleeding (DUB) underwent hysterectomy and wishes to take hormone replacement therapy. Physical examination, including breast examination, is normal, but X-ray shows osteoporosis. What is the treatment of choice?

Estrogen. ### **Explanation** The core principle in Hormone Replacement Therapy (HRT) is determining the presence of a uterus. **1. Why Estrogen is the Correct Answer:** The patient has undergone a **hysterectomy**. In women without a uterus, **Estrogen-only therapy (ERT)** is the treatment of choice. Estrogen effectively manages vasomotor symptoms and is highly effective in preventing and treating **osteoporosis** (as seen in this patient) by inhibiting osteoclast activity and reducing bone resorption. Since the uterus has been removed, there is no risk of estrogen-induced endometrial hyperplasia or carcinoma. **2. Why Other Options are Incorrect:** * **Progesterone (A):** Progesterone is not used as a standalone therapy for postmenopausal symptoms or osteoporosis. Its primary role in HRT is to protect the endometrium. * **Estrogen and Progesterone (B):** This "Combined HRT" is mandatory for women with an **intact uterus**. Adding progesterone to this specific patient is unnecessary and increases the risk of breast cancer and cardiovascular side effects without any clinical benefit, as she no longer has an endometrium to protect. * **None (D):** Treatment is indicated because the patient is symptomatic and has radiographic evidence of osteoporosis. ### **Clinical Pearls for NEET-PG:** * **Gold Standard for Osteoporosis:** While HRT is effective, **Bisphosphonates** are the first-line non-hormonal treatment for osteoporosis. However, if a postmenopausal woman is also symptomatic, HRT is an excellent choice. * **The "Uterus Rule":** * Uterus Present = Estrogen + Progesterone (to prevent endometrial CA). * Uterus Absent = Estrogen Only. * **Contraindications to HRT:** Undiagnosed vaginal bleeding, estrogen-dependent tumors (Breast/Endometrial CA), active thromboembolism (DVT/PE), and chronic liver disease. * **Window of Opportunity:** HRT is most beneficial when started within 10 years of menopause or before age 60.

Q: Which of the following is NOT a side effect of progesterone in hormone replacement therapy?

Leg cramps. **Explanation:** In Hormone Replacement Therapy (HRT), progesterone is primarily added to estrogen to prevent endometrial hyperplasia and carcinoma in women with an intact uterus. Understanding its side-effect profile is crucial for NEET-PG. **1. Why Leg Cramps is the Correct Answer:** Leg cramps are a classic side effect associated with **Estrogen** therapy, not progesterone. Estrogen can cause fluid retention and changes in electrolyte balance, leading to muscle cramps. In contrast, progesterone has a mild diuretic effect (antimineralocorticoid action), making it an unlikely cause of leg cramps. **2. Analysis of Incorrect Options (Progesterone Side Effects):** * **Acne:** Progesterone (especially synthetic progestins derived from 19-nortestosterone) has androgenic activity, which stimulates sebaceous glands, leading to acne and oily skin. * **Irritability:** Progesterone and its metabolites (like allopregnanolone) act on GABA receptors in the brain. While they often have a sedative effect, they can cause "PMS-like" symptoms, including irritability, mood swings, and depression in sensitive individuals. * **Constipation:** Progesterone acts as a smooth muscle relaxant. By reducing the motility of the gastrointestinal tract, it increases transit time, leading to constipation. **Clinical Pearls for NEET-PG:** * **The "Gold Standard" for Menopause:** HRT is the most effective treatment for vasomotor symptoms (hot flashes). * **Progesterone Requirement:** If a woman has undergone a hysterectomy, estrogen-only therapy (ERT) is given. Progesterone is *only* added if the uterus is present to protect the endometrium. * **Other Progesterone Side Effects:** Breast tenderness (mastalgia), bloating, and breakthrough bleeding. * **Metabolic Impact:** Progestins can sometimes negate the beneficial effects of estrogen on the lipid profile (by decreasing HDL).

Q: Why is progesterone added to estrogen hormone replacement therapy?

Postmenopausal lady with a uterus. In Hormone Replacement Therapy (HRT), the primary goal of adding progesterone is **endometrial protection**. [3] ### Why Option A is Correct In a postmenopausal woman with an intact uterus, administering **unopposed estrogen** (estrogen alone) leads to continuous proliferation of the endometrial lining. [1][4] Without the stabilizing effect of progesterone, this can result in endometrial hyperplasia and significantly increases the risk of **endometrial carcinoma**. [1][4] Adding a progestogen induces a "secretory" change in the endometrium and promotes periodic shedding, thereby neutralizing the oncogenic risk of estrogen. [3] ### Why Other Options are Incorrect * **Option B (TFS/AIS):** In Testicular Feminization Syndrome (Androgen Insensitivity Syndrome), the individual has a 46,XY karyotype and lacks a uterus. Since there is no endometrium to protect, progesterone is unnecessary; only estrogen is required for feminization and bone health. * **Option C (After Hysterectomy):** If the uterus has been surgically removed, there is no risk of endometrial cancer. These patients are prescribed **Estrogen-only HRT (ERT)**. Adding progesterone is avoided as it may unnecessarily increase the risk of breast cancer and cardiovascular side effects. [2] ### High-Yield NEET-PG Pearls * **Gold Standard:** Estrogen is the most effective treatment for vasomotor symptoms (hot flashes). [2] * **Exception:** If a patient has a history of **endometriosis** even after a hysterectomy, combined HRT may be considered to prevent the malignant transformation of residual ectopic endometrial tissue. * **Route:** Transdermal estrogen is preferred in patients with hypertension, gallstones, or a high risk of VTE, as it bypasses the first-pass hepatic metabolism. * **WHI Study Fact:** Combined HRT (E+P) is associated with a slightly increased risk of breast cancer compared to ERT alone.

Q: Menopause is defined as cessation of menstruation for how long?

12 consecutive months. **Explanation:** **1. Why 12 consecutive months is correct:** Menopause is a retrospective clinical diagnosis. It is defined as the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. Clinically, a woman is considered to have reached menopause only after experiencing **12 consecutive months of amenorrhea** in the absence of any other pathological or physiological cause (such as pregnancy or lactation). This duration is chosen because it marks the point where the likelihood of spontaneous ovulation or resumption of menses is statistically negligible. **2. Why other options are incorrect:** * **3 and 6 months (Options A & B):** These durations are characteristic of the **perimenopausal transition** or "secondary amenorrhea" (if occurring earlier in life). During perimenopause, cycles become irregular and "skipped periods" are common, but the ovaries may still produce enough estrogen to trigger occasional bleeding. Diagnosing menopause at 6 months would lead to many false positives. * **15 months (Option D):** While a woman at 15 months is certainly menopausal, this exceeds the standard diagnostic criteria. The 12-month mark is the globally accepted threshold (WHO/STRAW criteria). **3. NEET-PG High-Yield Pearls:** * **Average Age:** 51 years in the West; approximately **47.5–48 years** in India. * **Hormonal Profile:** The hallmark is a **rise in FSH (>40 IU/L)** and a **decrease in Estradiol (<20 pg/ml)**. FSH is the most sensitive diagnostic marker. * **Premature Ovarian Insufficiency (POI):** Menopause occurring before the age of **40**. * **Early Menopause:** Occurring between ages 40 and 45. * **Post-menopausal Bleeding:** Any vaginal bleeding occurring after the 12-month amenorrhea mark is "Post-menopausal bleeding" and must be investigated to rule out endometrial carcinoma.

Q: Hormone replacement therapy is not indicated for which of the following conditions?

Prevention of coronary artery disease. **Explanation:** The primary goal of Hormone Replacement Therapy (HRT) is the management of menopausal symptoms and the prevention of bone loss. **Why Option D is correct:** Historically, it was believed that HRT provided cardioprotection. However, large-scale clinical trials, specifically the **Women’s Health Initiative (WHI)**, demonstrated that HRT (especially combined estrogen-progestogen) does not prevent coronary artery disease (CAD). In fact, initiating HRT in older postmenopausal women may **increase** the risk of thromboembolic events and cardiovascular morbidity. Therefore, HRT is strictly **not indicated** for the primary or secondary prevention of CAD. **Analysis of Incorrect Options:** * **A. Urogenital atrophy:** Estrogen deficiency leads to vaginal dryness, dyspareunia, and urinary urgency. Low-dose topical or systemic HRT is the gold standard treatment for these symptoms. * **B. Vasomotor symptoms:** Hot flashes and night sweats are the most common indications for HRT. It remains the most effective treatment for moderate-to-severe vasomotor instability. * **C. Prevention of osteoporosis:** Estrogen inhibits osteoclast activity. HRT is FDA-approved for the prevention of postmenopausal osteoporosis, particularly in women at high risk of fractures who cannot tolerate other therapies. **High-Yield Clinical Pearls for NEET-PG:** * **Window of Opportunity Hypothesis:** HRT is safest and most effective when started within 10 years of menopause or before age 60. * **Contraindications:** Undiagnosed vaginal bleeding, active liver disease, history of VTE, and estrogen-dependent tumors (Breast/Endometrial CA). * **Addition of Progestogen:** In women with an intact uterus, progestogen must be added to estrogen to prevent **endometrial hyperplasia/carcinoma**. For women post-hysterectomy, Estrogen-only therapy (ERT) is used.

Question 1

In menopause, which of the following is not typically observed?

Accepted Answer

FSH

Answer

Cholesterol

Answer

Androgen

Answer

Cholesterol

Question 2

What is the best treatment for senile vaginitis?

Accepted Answer

Hormone Replacement Therapy (HRT) + Local estrogen cream

Answer

Hormone Replacement Therapy (HRT)

Answer

Local estrogen cream

Answer

Surgery

Question 3

What is the most common cause of postmenopausal bleeding?

Accepted Answer

Endometrial atrophy

Answer

Endometrial cancer

Answer

Endometrial polyps

Answer

Endometrial hyperplasia

Question 4

Hormone replacement therapy in post-menopausal women increases the risk of all the following conditions EXCEPT:

Accepted Answer

Colorectal cancer

Answer

Breast cancer

Answer

Stroke

Answer

Thromboembolism

Question 5

A 48-year-old female with severe dysfunctional uterine bleeding (DUB) underwent hysterectomy and wishes to take hormone replacement therapy. Physical examination, including breast examination, is normal, but X-ray shows osteoporosis. What is the treatment of choice?

Accepted Answer

Estrogen

Answer

Progesterone

Answer

Estrogen and progesterone

Answer

None

Question 6

Which of the following is NOT a side effect of progesterone in hormone replacement therapy?

Accepted Answer

Leg cramps

Answer

Acne

Answer

Irritability

Answer

Constipation

Question 7

Why is progesterone added to estrogen hormone replacement therapy?

Accepted Answer

Postmenopausal lady with a uterus

Answer

TFS/AIS syndrome

Answer

Postmenopausal patient after hysterectomy

Answer

All of the above

Question 8

A 50-year-old woman, who has attained menopause, presents with one episode of post-vaginal bleeding. Which of the following investigations should be performed?

Accepted Answer

Assess for history of hormone replacement therapy, Pap smear, and endometrial biopsy

Answer

Assess for history of hormone replacement therapy and endometrial biopsy

Answer

Hysterectomy and Pap smear

Answer

Hysterectomy, dysfunctional uterine bleeding workup, and endometrial biopsy

Question 9

Menopause is defined as cessation of menstruation for how long?

Accepted Answer

12 consecutive months

Answer

3 consecutive months

Answer

6 consecutive months

Answer

15 consecutive months

Question 10

Hormone replacement therapy is not indicated for which of the following conditions?

Accepted Answer

Prevention of coronary artery disease

Answer

Urogenital atrophy

Answer

Vasomotor symptoms

Answer

Prevention of osteoporosis

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?